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Abstract
18F-fluorodeoxyglucose (FDG) PET/CT is a pivotal imaging modality for cancer imaging, assisting diagnosis, staging
of patients with newly diagnosed malignancy, restaging following therapy and surveillance. Interpretation requires
integration of the metabolic and anatomic findings provided by the PET and CT components which transcend the
knowledge base isolated in the worlds of nuclear medicine and radiology, respectively. In the manuscript we detail
our approach to reviewing and reporting a PET/CT study using the most commonly used radiotracer, FDG. This
encompasses how we display, threshold intensity of images and sequence our review, which are essential for
accurate interpretation. For interpretation, it is important to be aware of benign variants that demonstrate high
glycolytic activity, and pathologic lesions which may not be FDG-avid, and understand the physiologic and
biochemical basis of these findings. Whilst FDG PET/CT performs well in the conventional imaging paradigm of
identifying, counting and measuring tumour extent, a key paradigm change is its ability to non-invasively measure
glycolytic metabolism. Integrating this “metabolic signature” into interpretation enables improved accuracy and
characterisation of disease providing important prognostic information that may confer a high management impact
and enable better personalised patient care.
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Background
18F-fluorodeoxyglucose (FDG) PET/CT imaging has be-
come a key modality for imaging patients with cancer
[1]. The process of reviewing PET/CT studies involves
integration of the metabolic findings from the FDG
component combined with the anatomical information
provided by the CT component. This is a modality with
many patterns of structural, physiologic and biochemical
abnormalities that transcend the boundaries previously
isolated in the worlds of nuclear medicine or radiology
in characterising pathological conditions, particularly
including cancer. Whilst there is a wealth of literature
addressing the utility of PET in a large array of malig-
nancies, the art of how to review and interpret PET/CT
is generally acquired like an apprentice and not well
addressed in the literature. In this article, we detail our
approach to reviewing a PET/CT study using the most
commonly used tracer, FDG. Future articles in this series
will address the use of other tracers pertinent to other
cancers.
Acquisition
Patient preparation is important in acquiring good qual-
ity studies and it is the responsibility of the PET special-
ist to ensure that appropriate protocols are in place to
prevent non-diagnostic or suboptimal studies. Detailed
discussion of acquisition parameters is beyond the scope
of this review but includes preparation of diabetic
patients, strategies to minimise brown fat activation, as
well as prescription of the extent of the field-of-view and
the positioning of the patient to address the clinical
question. For example, we position the patient with their
arms down for head and neck malignancies but with
their arms up for thoracic cancers. It is also important
to determine the methodology to be used for CT acqui-
sition. This varies widely according to local practice and
our approach is discussed in further detail later in this
manuscript.
An important aspect of interpretation is assessment of
the technical adequacy of the study and ideally should
be done before the patient leaves the department to
enable repeat acquisition of any critical regions inad-
equately assessed on the initial examination.
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Optimal windowing of PET images
In any PET/CT study there are three discrete image sets
that require display. These are the stand-alone PET data,
the CT and the fused PET/CT images. Correct and con-
sistent windowing is key to avoid both over- and under-
interpretation of findings and to maintain the consistency
required for accurate comparison of multiple studies. This
also aids presentation of findings to referrers and patients.
The primary data from PET has been traditionally dis-
played on a linear grey scale. This is because the human eye
is adept at discerning subtle differences in contrast from
white through grey to black. The lower threshold of this dis-
play should be set at zero (white) while the upper threshold
needs to be manipulated to obtain consistent display of
physiological and pathologic uptake. Consequently, the in-
tensity of normal tissues should be within the lower-to-
middle portion of the dynamic range while the upper range
used to demonstrate the range of intensities that might exist
in pathological processes characterised by high glycolytic ac-
tivity. By maintaining a reasonable spectrum of grey shades
for display of normal tissues it is possible to detect faint
lesions in areas of low background activity, such as the lung.
Our preference is to have the most intense voxels in
the normal liver appearing just below the middle of the
grey scale range, which will be a light to mid-grey
(Fig. 1a). Use of a colour scale is required for superim-
position of functional images over the CT. We prefer to
use the "rainblow" colour scale that has low activity re-
gions displayed in the blue-green range and higher in-
tensity regions in the orange-red spectrum. With this
colour scale, the liver will generally appear blue with
flecks of green with adjusgment if not (Fig. 1). This
corresponds to an upper SUV window threshold of 8–10
and will usually achieve an appropriate contrast, except
in very large patients in whom this may make the liver
too dark. This is because adipose tissue contributes to the
weight correction of administered activity, which is used
for SUV calculation, but does not itself take up FDG. This
means that more FDG is available for uptake in other tis-
sues, including the liver. However, this may be counter-
acted by deposition of fat in the liver in obese subjects.
This will usually be apparent by virtue of increased relative
uptake in the spleen, which is generally marginally less in-
tense than the liver. The brain will usually be nearly black
with this scaling. This is unless cortical glycolytic activity
is reduced by metabolic processes, especially by hypergly-
caemia, or neurological conditions such as dementia. In
children requiring general anaesthesia during the uptake
and scanning procedure, cortical activity can also be sig-
nificantly reduced. There are also changes in the brain
during childhood maturation [2].
Under fasting conditions, glucose and its analogue,
FDG, have facilitated uptake into the liver and therefore
generally this organ has significantly higher activity than
the blood. By definition, any structure with uptake more
intense than that in the liver must also have facilitated
FDG uptake and trapping. The advantage of using the
liver as a reference tissue is also aided by this organ having
rather low variability in metabolic activity [3]. It is, how-
ever, inappropriate to threshold for liver uptake if it is not
deemed normal due to diffuse malignant infiltration, sar-
coidosis, or fatty infiltration. This can be detected visually
if there is marked discrepancy between liver and spleen
intensity, although with sarcoidosis or lymphoma both
Fig. 1 The PET window intensity is adjusted so that the liver appears light to mid-grey on the grey scale, corresponding to flecks of green in the
liver on the rainbow colour scale. Despite the difference in SUVmax of the liver secondary to differences in weights of the two patients (a and b),
the liver intensity this appears the same in both patients
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can be increased. Our practice of thresholding the grey
and colour scale to liver as detailed above results in similar
image intensity to a fixed upper SUV threshold of 8 to 10.
However, using the liver as a reference enables consistent
windowing of images over a series of time-points within
and between individuals and compensates for variations
that might be caused by inaccuracies in SUV measure-
ment between scans, issues related to dose calibration
errors, extravasation of dose, different uptake periods or
technical differences if rescanned on a different type of
PET/CT device. When the liver is abnormal and cannot
be used as a reference organ, we use the default SUV set-
ting of an upper SUV threshold of 8. The same SUV
threshold as that used for the whole body study should be
applied when additional separate series are acquired (e.g.
of the limbs) that do not encompass the liver.
Since some disease processes can have extremely high
SUV values, it may be necessary to increase the upper
threshold to appreciate the dynamic range of glycolytic
activity. This is particularly important in diseases where
there can be considerable heterogeneity in disease. Fol-
licular lymphoma, in which most lesions can have a
SUVmax in excess of 10 but regions of high-grade trans-
formation with corresponding values of >15, is a particu-
lar case in point. Standard thresholds provide a good
representation of the extent of disease but using a higher
upper threshold to display the images can help to iden-
tify the regions of likely transformation or different
disease biology and can aid biopsy site selection (Fig. 2).
This “rainbow” colour scale has relatively abrupt
changes in colour, which enable easy differentiation of up-
take intensity in the low, mid or high range. It is also a
psychologically intuitive scheme with blue-green shades
being cool colours whereas yellow-orange colours denote
caution and reds, danger. Like a traffic light, we teach our
referrers that these spectrums usually represent benign,
equivocal and pathological findings, respectively. Clearly,
this is an oversimplification, but it enables one to eyeball
the PET image and decide if the uptake is of low, moder-
ate or high metabolic activity.
It should, however, be noted that this can be a danger-
ous scale to use if there isn’t a disciplined and consistent
use of the threshold setting principles detailed above
since it is easy to “dial” lesions in and out. We often see
studies, particularly from practices that have more ex-
perience with CT than PET, that have clearly had the
threshold altered to render them red, or not, depending
on whether the reader considers them more, or less,
likely to be malignant based on the CT characteristics.
While this might be a reasonable approach to communi-
cate the site of a lesion, it diminishes the power of PET
to characterise disease based on the degree of its meta-
bolic activity. To avoid the risks associated with this
scale, some manufacturers set the default colour scale to
a dichotomous range, such as blue-yellow or brown-gold
(see Fig. 3). This does not carry the psychological power
of the rainbow scale but can be useful for displaying sites
of presumed disease against the background of CT while
reducing the risk of false-positive results due to use of
an inappropriate display threshold. The “rainbow” colour
scale may also be difficult for individuals with colour
blindness to interpret.
We dislike colour scales with a continuous spectrum
of a single colour, such as the commonly used “hot
metal” scale, as these provide poor contrast between low
and high intensity, and background CT images. The
human eye is very sensitive in detecting differences of
intensity within a grey scale but not so good within a
single colour spectrum. Consequently, with “hot metal”
or similar colour scales, it is difficult to qualitatively
Fig. 2 This patient presented with suspected metastatic nasopharyngeal cancer. Initial workup with endoscopic ultrasound and biopsy of the
subcarinal node was non-diagnostic with necrotic tissue. FDG PET/CT demonstrates very intense uptake at all sites with lower uptake in the
subcarinal node, only evident when widening the PET window. The findings suggest a different tumour biology at this site with necrosis. When
feasible, we recommend biopsy of the most FDG-avid lesion which likely represents the site of most aggressive disease and least likely to be
non-diagnostic. In summary, the PET study windowed narrowly is primed for sensitivity whereas a wider window enables superior characterisation
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assess an image and know where the intensity of abnor-
mality lies within in the spectrum. Moreover, the highest
intensity on this scale is sometimes white, which is
essentially uninterpretable when superimposed on a grey
scale CT image.
Standardised windows have been developed that set
upper and lower levels for Hounsfield units that opti-
mally display the range of densities pertinent for a par-
ticular tissue. We routinely review soft tissue, lung and
bone windows but in appropriate situations will use
other specialised windows. Just as the profession has im-
posed certain discipline in the use of standardised win-
dows for use on CT, we believe that there should be
greater harmonisation of display of PET images.
PET/CT review sequence
Initial review of the images blinded to patient history or
indication is valuable as it enables an unbiased assessment.
The black-and-white cine maximum intensity projection
(MIP) is foremost in this initial review. This enables a
“gestalt” impression of the study. The reconstruction
method of these images tends to suppress noise and high-
light regions of increased activity. Furthermore, the brain
can appreciate these images as being volumetric, especially
when rotating. This particularly aids recognition of the
shape of regions increased activity, and particularly
whether they are spherical, tubular or geographic. For the
importance of this, see “Rod’s Rules” in the introduction
to the “How We Read” series [4]. With experience, key
findings are often established within seconds by review of
this series. By definition, this image is relatively insensitive
to regions of reduced activity.
Next, we review the coronal PET images and triangu-
late apparent abnormalities on other planes and the MIP
image. It is important to review these images on a work-
station that has capacity to triangulate findings in axial,
coronal and sagittal planes. We find the coronal images
particularly helpful for detecting small abnormalities, par-
ticularly within the lungs and subcutaneous tissue. Any le-
sions identified on the PET are then correlated with the CT
images, reviewing soft tissue, lung and bone windows as ap-
propriate to the location of the abnormality. We selectively
review the non-attenuation corrected (NAC) series when
there is uncertainty about possible reconstruction artefacts
due to metallic objects or patient movement between PET
and CT components. Finally, it is important to widen the
PET window in order to review the brain, otherwise easily
discernible abnormalities can be missed (see Fig. 4).
Only after completing review of the stand-alone PET im-
ages we review the fused PET/CT images. This is a quite
different process to that of many practices where the trans-
axial CT is scrolled through and any structural abnormal-
ities identified are then correlated with the fused PET/CT
image. This is often the preferred method of experienced
radiologists who are sometimes more comfortable review-
ing the CT than looking at stand-alone PET images. This
approach tends to then use FDG information as an alterna-
tive contrast agent rather than as the primary data of a
PET/CT study. Those disposed to this method will also
generally prefer to obtain a full diagnostic CT as part of the
examination. The advantages and disadvantages of these
differing methods will be discussed subsequently.
As a final pass, we review the CT images sequentially
on soft tissue, lung and bone windows to identify struc-
tural abnormalities not previously identified on PET
Fig. 3 Patient with metastatic colorectal carcinoma and hepatic metastasis. The fused image is presented in different colour scales. We recommend
using the “rainbow” scale owing to the superior tumour-to-liver contrast compared to other commonly used colour maps
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review. Interpretation of structural abnormalities that
are not associated with metabolic abnormality requires
particular care and can give significant insights into the
nature of pathological processes.
Interpretation of PET/CT
The reader is directed to the initial article in this series,
which details many of the principles that we use in for-
mulating an impression of a scan, in reporting its find-
ings and reaching a conclusion.
Tumours grow as spheres: differentiating malignant from
inflammatory aetiology
When high metabolic activity is present, one of the pri-
mary aims is to ascertain if the aetiology is malignant, be-
nign or inflammatory. In early PET literature focusing on
analysis of solitary pulmonary nodules, some researchers
defined malignancy based on a SUVmax threshold of
greater than 2.5 [5]. We contend that SUV analysis has
virtually no role in this setting. Far more important than
the SUVmax is the pattern rather than intensity of meta-
bolic abnormality and the correlative CT findings. Our
number one rule is that tumours grow as spheres, whereas
inflammatory processes are typically linear and track along
soft tissue boundaries such as pleural surfaces or fascial
planes (see Fig. 5).
Occam's razor teaches us to look for a single cause
that will explain all the findings on a particular study.
One of the most challenging aspects of oncologic FDG
PET/CT review, however, is to recognise all the patterns
of metabolic activity that are not malignant and which
consequently confound interpretation. Many benign and
inflammatory processes are also associated with high
glycolytic activity. Whilst some require further investi-
gation, many have characteristic appearances that en-
able confident characterisation. A variety of potential
pitfalls are detailed in Table 1, most of which do not
require further investigation. Recognition of other pit-
falls requires knowledge of the typical pattern of the
various malignancies but is beyond the scope of this
review. Future articles in the “How I Read” series will
address the specific details of reading PET/CT in
various cancers.
Commonality of “Metabolic Signature”
The intensity of uptake in metastases usually parallels
that in the primary site of disease. If not, another aeti-
ology should be considered. For example, discordant
low-grade activity in an enlarged lymph node in the set-
ting of intense uptake in the primary tumour suggests it
is unlikely malignant and more likely inflammatory or
reactive. By CT criteria the enlarged node is ‘pathologic’
but the discordantly low metabolic signature further
characterises this is as non-malignant since such a node
is not subject to partial volume effects and therefore the
intensity of uptake should be similar to the primary site.
The exception is when the lymph node is centrally nec-
rotic as a small rim of viable tumour is subject to partial
volume effects with expectant lower intensity of uptake;
integrating the CT morphology is therefore critical to
reaching an accurate interpretation (see Fig. 9). Small
nodes that are visualised on PET are conversely much
more likely to be metastatic as such nodes are subject to
partial volume effects.
Fig. 4 Patient with diffuse large B cell lymphoma. On the standard windowing, no abnormality is readily identified in the brain (a coronal & axial slice,
b MIP image). By increasing the upper SUV threshold, abnormal uptake becomes readily becomes visible (c MIP image, d coronal & axial slice). This
corresponded to a MRI abnormality which was not reported prospectively but identified following targeted review after the PET scan. Changing the
PET window so that abnormalities can be identified above physiologic brain activity should be a routine component of image review
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The exception to this rule is tumours with a propensity
for tumour heterogeneity at different sites. In follicular
lymphoma or chronic lymphocytic leukaemia, discordant
sites of high metabolic activity can be a specific finding for
transformed disease. In malignancies with a range of well-
to poorly-differentiated phenotypes (particularly endocrine
tumours), it is possible to visualise tumour heterogeneity
with different grades of disease at varying sites. The com-
bination of FDG and a more specific tracer, which visual-
ises the well-differentiated disease can be very useful to
characterise this phenomenon, e.g. radio-iodine imaging
for thyroid cancer or somatostatin receptor imaging for
neuroendocrine tumours [6].
Move beyond lesion counting and size measurement to
lesion characterisation
The classical PET/CT indications involve primary staging,
therapeutic monitoring, detection of recurrence disease or
surveillance. The ability to non-invasively measure glyco-
lytic activity, defining what we refer to as the “metabolic
signature”, however, is a key feature of FDG PET/CT that
is overlooked by many reporters. For the majority of ma-
lignant processes, the intensity of metabolic abnormality
correlates with degree of aggressiveness or proliferative
rate. For a metastatic malignant process that demonstrates
no or minimal metabolic abnormality, this is usually a
marker of low proliferative rate and indolent phenotype.
Applying conventional diagnostic imaging paradigms, a
negative PET/CT study in a patient with biopsy proven
malignancy would be considered false-negative. A more
useful report, however, would highlight the powerful prog-
nostic information this provides. Providing such prognos-
tic information was formerly the domain of pathology; a
report which ignores the intensity of metabolic abnormal-
ity is missing a key utility of FDG PET/CT. Descriptively,
we define SUV < 5 as “low intensity”, 5–10 as “moderate”,
10–15 as “intense” and >15 as “very intense”. Document-
ing the actual SUV in the report can be useful to avoid
ambiguity with qualitative statements that may be inter-
preted variably.
Evolving literature suggests that intensity of uptake is
an independent prognostic factor and in some tumour
subtypes superior to histopathologic characterisation.
Tumours with low uptake and commensurate indolent
phenotype may include papillary thyroid cancer, neuro-
endocrine tumours, clear cell renal carcinomas and
breast carcinoma. Each of these, however, can also dem-
onstrate high intensity uptake commensurate with their
spectrum of well- to poorly-differentiated phenotype,
with the more aggressive phenotypes demonstrating high
intensity uptake commensurate with their higher prolif-
erative rate. PET can be used to guide targeted biopsy of
the most intense site of metabolic activity.
There are some important exceptions to this broad
principle as detailed below:
FDG negative but aggressive malignancy
The vast majority of aggressive malignant processes use
aerobic glycolysis to derive a substantial amount of their
energy, converting glucose to lactate by denying pyruvate
Fig. 5 This patient had suspicion of pelvic recurrence in the setting of prior surgical excision for rectal carcinoma. There was intense uptake in the
known pre-sacral soft tissue thickening (a) and (c) (red arrow) with SUVmax of 11. The linear morphology on the coronal image (b) suggested this was
more likely inflammatory than malignant. A separate linear tract of metabolic activity was also seen (green arrow) extending from the pre-sacral
abnormality to the peri-anal region (not shown). All abnormalities resolved following antiobiotic therapy confirming inflammatory aetiology
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Table 1 Patterns of uptake in benign neoplasms, post treatment changes and inflammatory processes which can mimic malignancy
Pathology Pattern of uptake and comment
Benign neoplasms
Thyroid Hurthle cell adenoma (see Fig. 10a) Focal and intense thyroid uptake. Virtually diagnostic if there is a calcified egg-shell
appearance on CT, but this feature is not always present.
Renal oncocytoma (Fig. 10b) Can have similar anatomic appearance on CT to renal cell carcinoma
Parotid oncocytoma (Warthin’s tumours) (see Fig. 10c) Focal and intense uptake in the parotid corresponding to a soft tissue nodule of
increased density relative to normal parotid tissue
Colorectal adenoma These are typically focal and may be identified on CT if pedunculated. Depending on the
clinical context, these generally warrant endoscopic evaluation as high FDG-avidity
generally reflects at least high-grade dysplasia.
Elastofibromi dorsi Linear low-to-moderate uptake corresponding to muscle-like soft tissue abnormality in
posterior chest wall [17]
Post treatment changes
Post talc pleurodesis (Fig. 6) Multi-focal intense uptake corresponding to high-density material (talc) on CT. Can be
extensive and persist indefinitely. FDG-avidity should be very closely matched to the sites
of CT density and if performed for prior pleural malignancy, sites of pleural uptake with
corresponding CT density should be considered to be malignant deposits
Post radiotherapy inflammatory change Geographic (linear) change conforming to the radiation treatment field. Surrounding very
low grade ‘haze’ of uptake within muscle and soft tissue can be apparent
Fat necrosis Most commonly located in mesenteric fat after therapy in patients with lymphoma [10].
Focal moderate-to-intense uptake corresponding to nodule with density between that of
soft tissue and fat. Classic appearance of ‘donut shape’ abnormality sometimes apparent.
High and symmetric tonsillar activity post
chemotherapy
Commonly seen in patients with haematologic malignancies following chemotherapy,
reflecting lymphoid repopulation/hyperplasia. This is commonly accompanied by lower
grade reactive jugulodiagastric nodal activity that should not be misinterpreted as
recurrent lymphoma.
Appendiceal linear activity Another region of rich lymphoid tissue, in which increased activity is seen post
treatment, particularly in younger patients as described above.
Dystrophic calcification Following treatment some tumours calcify with pathologic correlate of xanthogranulomatosis
inflammatory change. High metabolic activity can predate appearance of calcification on CT.
Myositis ossificians is a variant of this process and should be considered for fusiform and focal
intramuscular lesions, even in the absence of calcification. This can be an important diagnosis
as this disease can mimic a sarcoma on MRI and even pathology.
Immune related inflammatory response Following treatment with anti-CTLA4 antibodies (eg. iplilumab) and much less commonly
with PD1 inhibitors (eg. pembrozulimab) low-to-moderate uptake in lymph nodes in
drainage sites from tumours can be observed. Associated homogenous diffuse splenic
uptake can assist identify this pattern. Autoimmune thyroiditis, colitis, adrenalitis and
hypohysitis can also be identified in this therapeutic setting.
Inflammatory processes
Hilar and mediastinal nodal activity, pre-caval nodal
activity (see Fig. 7)
A common finding with symmetry being the key finding pointing to an inflammatory/
reactive aetiology. Symmetrical nodal activity of malignant aetiology is exceedingly rare.
We have noted higher incidence of this reactive pattern in patients from rural areas. In
association, it is quite frequent to visualise similar intensity metabolic abnormality in the
subdiaphragmatic pre-caval region.
Marrow uptake Diffuse marrow uptake is a feature of a systemic inflammatory system and can be a
feature of an infectious or septic process. It may be accompanied by mild diffuse
increased splenic activity. This is also seen with Hodgkin’s lymphoma where only focal
high intensity abnormalities should be interpreted as marrow infiltration.
Physiologic variants
Anal sphincter activity Midline, ring morphology, air-filled rectum (“polite sign”)
Fallopian tube and ovary (see Fig. 8) In mid-cycle it is frequent to observe bilateral curvilinear increased fallopian tube activity
+/− focal unilateral ovarian follicular activity [18]
Brown fat activity Whilst typical features of symmetric cervical, supraclavicular, axillary and para-vertebral fat
activity is easily identified, locations such as para-adrenal region should also be recognised.
Administration of propranolol 10–20 mg orally 60 minutes prior FDG administration is
effective in suppressing brown fat. Rarely, brown fat activation can be a clue to an
underlying functional phaeochromocytoma or paraganglioma. Diffuse increased white fat
uptake can also occur following administration of steroids [19].
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access to the tricarboxylic acid cycle. This is termed the
Warburg effect [7]. There, however, are a significant
minority of tumours that utilise substrates other glu-
cose such as glutamine or fatty acids as a source of the
carbon atoms required for growth and proliferation.
These allow glucose to be diverted into the pentose
phosphate shunt pathway. The utility of FDG PET is
diminished in this setting. This includes a subset of
diffuse gastric adenocarcinomas, signet cell colonic
adenocarcinomas and some sarcomas, particularly lipo-
sarcoma. Histologically, these are characterised by tu-
mours with high proliferative rate but minimal GLUT-1
expression. There may be a role for other radiotracers
such as fluorothymidine (FLT) or amino acid substrates in
this setting.
FDG PET/CT has a finite resolution. However, this con-
tinues to improve with each generation of PET technol-
ogy. Apparent FDG uptake is reduced in small volume
disease due to partial volume effects, and also in areas of
subject to movement, mainly due to respiration. The ap-
parent intensity of uptake in small pulmonary metastases
will be reduced due to both these phenomena. New recon-
struction algorithms such as point spread function model-
ling can significantly improve lesion contrast but may also
significantly impact the SUV of small lesions. Attempts to
harmonise the semi-quantitative analysis of PET data
require methods to deal with differences introduced by
reconstruction algorithms [8]. Reduction in activity owing
to respiratory motion is most evident in the lung bases
and also the dome of the liver. Acquiring images with
Table 1 Patterns of uptake in benign neoplasms, post treatment changes and inflammatory processes which can mimic malignancy
(Continued)
Large and small bowel activity Diffuse increased uptake is seen in patients on metformin, which increases colonic
glycolysis. Cessation of metformin for 48 h will reduce bowel related activity [20]; this can
be a useful manoeuvre if is interfering with scan interpretation. In patients not on
metformin, physiologic bowel activity can be seen as part of normal peristalsis.
Ureteric activity The ureter can follow a tortuous course which can result in apparent focal activity which
can be difficult to distinguish from nodal activity. A delayed phase image after injection
of intravenous contrast can assist by enabling confident localisation to the ureter.
Gallbladder luminal activity Uncommon finding but seen in patients with a delayed uptake phase who have eaten
after initial uptake period; this typically occurs when there is equipment failure
necessitating very delayed imaging [21].
FDG ‘pulmonary emboli’ Iatrogenic micro-embolism can occur when blood is withdrawn from vein and mixed with
FDG, and then re-injected. The complete absence of anatomic abnormality corresponding
to focal very intense activity (SUV > 30) is very likely to represent this phenomenon.
Fig. 6 Patient with prior lung malignancy presents for surveillance. The study demonstrates a typical appearance of inflammatory change post
talc pleurodesis with intense multi-focal uptake evident throughout the pleural surface (a). On the axial PET/CT (b) and CT (c) the high focal up-
take correlates with a site of talc on CT recognised by its high density. Such change can persistent for many years after pleurodesis
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respiratory gating can be useful [9] but with experi-
ence this can often be recognised visually. As previ-
ously alluded to, enlarged necrotic nodes with only a
thin rim of tumour are also subject to significant par-
tial volume effects and can thus appear FDG negative
(Fig. 9). Similarly, some aggressive sarcomas or mu-
cinous tumours can also appear PET negative when
the signal from cancer cells is dominated by the low
uptake in adjacent by extra-cellular matrix or mucin
production.
Intense FDG uptake but indolent neoplasm
Some tumours harbour mutations that result in defective
aerobic mitochondrial energy metabolism, effectively
simulating the Warburg effect. Due to these mutations
and consequent inefficient oxidative phosphorylation, a
high amount of glucose is required for ATP production.
Mutations in subunits of succinate dehydrogenase (e.g.
SDHB) found in patients with hereditary paraganglioma
and pheochromocytoma highlight this phenomenon.
These have intense uptake on FDG PET/CT despite often
Fig. 7 Patient with non-small cell lung cancer treated with curative intent radiotherapy. Post treatment restaging PET/CT demonstrated a complete
metabolic response (a–d, c upper SUV threshold adjusted to liver background as detailed above, d upper SUV threshold of 5). Follow-up CT 9 months
later demonstrated enlargement of multiple mediastinal nodes considered likely to represent malignant aetiology. Repeat PET/CT (e–i) demonstrated
low-to-moderate uptake in these nodes. Given the symmetry of distribution in hilar and mediastinal nodes the aetiology was considered inflammatory,
which was confirmed by resolution on follow-up. Thresholding the PET with a SUV threshold of 5 (h–i) might lead to erroneous description of intense
uptake and interpretation as malignant in aetiology
Fig. 8 Appearance of physiologic adnexal uptake observed mid-cycle. Although the metabolic activity is high, on the rotating MIP images (a anterior
and lateral) the activity is bilateral and curvilinear, characteristic of fallopian tube activity (b). Unilateral focal ovarian follicular activity is frequently seen
in association with this finding
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having low proliferative rate. Benign oncocytomas,
such as parotid, thyroid Hurthle cell or renal oncocy-
tomas also harbour mutations of mitochrondrial oxi-
dative phosphorylation resulting in high FDG activity
(see Fig. 10). Uterine fibroids, hepatic adenomas,
fibroadenomas of the breast and desmoid tumours
are benign or relatively benign lesions that can have
quite high FDG-avidity.
Beware the staging scan which is actually a response
assessment scan
Metabolic activity switches off rapidly following initi-
ation of therapy. For example, following initiating of
the tyrosine kinase inhibitor, imatinib, for treatment
for gastrointestinal stromal tumours (GIST) metabolic
activity changes from intense to negative within 24
hours. The same principle applies in a wide variety of
Fig. 9 Patient with HPV-p16 positive cervical squamous cell carcinoma presents for staging. FDG PET (a) demonstrates subtle uptake in an
enlarged right external node (b) which would be difficult to discern without knowledge of the CT findings. Correlation with prior contrast-
enhanced CT (c) demonstrates the node has rim enhancement and central necrosis consistent with malignant aetiology. The rim of viable
tumour is thin and below the resolution of PET imaging explaining the absence of significant uptake. Integration of CT morphology is critical
in this case for accurate interpretation
Fig. 10 Three different patients with (a) Hurthle cell adenoma (thyroid oncocytoma), (b) renal oncocytoma and (c) Parotid Warthin’s tumour (parotid
oncocytoma). Each has high SUVmax of 45, 22 and 35, respectively. In each case, the abnormality was present on imaging more than one year prior
and unchanged in size. The very intense FDG uptake could be interpreted as suspicious for aggressive malignancy but the lack of temporal change
was inconsistent with this. The lack of progression in a thyroid, renal or parotid lesion with very intense uptake is pathognomonic of benign
oncocytomas
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circumstances so it is important to be aware whether
or not the patient has commenced active therapy.
Common examples where patients have commenced
active therapy but the referrer is requesting “staging”
includes hormonal therapy (eg. tamoxifen) in breast
cancer, oral capecitabine in colorectal cancer or high
dose steroids in Hodgkin’s lymphoma. In these set-
ting, sites of disease may not be metabolically active
confirming effectiveness of active therapy, but limiting
the utility of PET to provide accurate staging. Accur-
ate staging may not possible even shortly after treat-
ment has commenced, a paradigm that is different
from anatomic imaging where it takes some weeks for
changes to occur. It is therefore critical to perform
PET staging before commencement of anti-tumour
therapy.
Integration of CT data
Integrating the anatomic information provided by CT is
important for accurate PET/CT interpretation as it may
increase the specificity and sensitivity of PET findings.
Detailed knowledge of the anatomic appearance of patho-
logic, inflammatory and benign processes is therefore crit-
ical to correctly interpret PET/CT. For example, focal
intense abnormality on PET alone indicative of residual or
recurrent lymphoma, may be revised to fat necrosis when
CT appearances are integrated [10]. Likewise, lack of
uptake in a lymph node may be revised from benign to
malignant when the CT appearances of contrast enhance-
ment rim enhancement and necrosis are integrated.
Many groups perform diagnostic CT studies with
PET using a full-dose and contrast-enhanced acquisi-
tion including specialised regional protocols. In part,
whether to perform this routinely depends on local
practices, credentialing of reporting specialists, and
reimbursement schemes. The potential advantage of
routine diagnostic CT is improved anatomic loca-
lisation and definition, although we contend that low
dose CT images reconstructed on modern generation
devices usually provide sufficient detail with limited
incremental value from “dedicated CT”. Moreover, pa-
tients have frequently already had a recent diagnostic
CT, although this may diminish with increased utilisa-
tion of PET/CT as the first test rather than the last test.
Without intravenous contrast, additional identification
of typical oncologic complications such as pulmonary
embolism or venous thrombosis cannot be identified.
Nevertheless, if a “low dose CT” technique is utilised, it
should not be considered “non-diagnostic” as it pro-
vides rich anatomic detail.
There are, however, situations where the acquisition of
contrast-enhanced CT is preferred or can be tailored
based on findings on the whole body low dose PET/CT
without contrast in order to clarify the nature or
anatomical relations of FDG-avid foci. Situations where
we advocate full-dose, contrast-enhanced CT include lo-
calisation of cervical lymph nodes in head and neck can-
cer in the absence of systemic metastasis, especially to
define necrotic nodes, the evaluation of liver metastases
suitable for resection and for definition of pancreatic
lesions [11]. In other cases, specific interventions, such
as use of hyoscine and water to distend the stomach [12]
or respiratory gating to resolve the nature of lesions that
are subject to respiratory blurring [9], can further en-
hance diagnostic accuracy. The objective should always
to utilise the complementary strengths of each modality
to provide accurate diagnostic information pertinent to
the individual patient’s care with the minimum risk and
greatest convenience. Sometimes this will involve a dedi-
cated and individualised CT acquisition protocol but for
other patients, a non-contrast, low-dose protocol will be
sufficient. Despite the logistic impost, our preference is
to determine the need for and acquisition parameters for
contrast-enhanced CT based on immediate review of the
whole-body study without contrast and then doing a de-
tailed loco-regional assessment as an additional acquisi-
tion, including pharmacological intervention if this may
aid the diagnostic process.
When performing dedicated CT with higher dose and
administration of intravenous/oral contrast may enable
detection of abnormalities that are not FDG-avid, such
as small hepatic or pulmonary lesions, many of these ab-
normalities are not malignant and represent incidental
benign aetiology, thus potentially decreasing specificity.
Just as integration of CT increases specificity of PET
findings as discussed above, the converse can also be
true. In malignancies which are known or expected to
have high FDG uptake, we advise caution in reporting
incidental findings on CT that are not FDG-avid as sus-
picious or malignant. Furthermore, equivocal abnormal-
ities by CT criteria alone (e.g. an ovarian cyst) that
would ordinarily mandate further investigation, may be
characterised by the absence of FDG uptake as being
extremely likely benign. The integration of PET to
characterise incidental CT findings is important to
decrease further investigations that may usually be
mandated with CT alone. Over-sensitive reporting can
lead to patient harm, or, worse still, might deny po-
tentially curative treatment.
Restaging studies
For oncologic FDG PET/CT, comparison with prior studies
is critical to answer the clinical question. If the study is per-
formed as an “interim” restaging study after commence-
ment of therapy but before completion, in order to reach a
valid or clinically useful conclusion findings must be inter-
preted in the context of known changes that occur at a
specific timing and type of therapy. The most well studied
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use of interim PET is in Hodgkin’s lymphoma where repeat
PET after two cycles of ABVD-chemotherapy provides
powerful prognostic information and may improve out-
comes by enabling early change of management. The use
of interim FDG PET/CT is now a well established tech-
nique in high grade lymphoma with standardised reporting
criteria [13].
In our experience, critical errors of interpretation can
be made by comparison only with the prior study. For
example, if PET/CT is performed too frequently, find-
ings may be erroneously described as stable whereas
comparison with the baseline study may clearly demon-
strate regression or progression. Review of multiple ser-
ial MIP images over the course of therapies can enable
rapid appreciation of changes not evident by comparison
with the prior study. Knowledge of when treatment
commenced is also critical for correct interpretation. For
example, a restaging PET/CT performed 3 months after
a baseline study demonstrating a “mixed response” with
some lesions appearing larger and others smaller, could
be better explained by progressive disease and subse-
quent response to therapy if it was known that therapy
was only commenced 1 month prior to the restaging
scan, with the initial scan therefore not representing a
true baseline.
Formulating reports
We aim to provide a succinct and structured report
answering the clinical question under the following sub-
headings:
▪ Clinical notes: The aim of this section is to identify
the clinical question that needs to be addressed in
the conclusion. Unfortunately, complete clinical
information is frequently not provided by the
referring physician, and therefore alternative sources
of information must be sought including from the
patient directly, via a patient questionnaire (see
Table 2), electronic records or contacting the
referrer.
▪ Technique: We suggest including the following
minimum details to document the method so that
others can be reassured that the scan was technically
adequate, and to enable similar acquisition parameters
for subsequent scans: acquisition field-of-view, model
of PET/CT scanner, reconstruction technique (e.g. use
of time-of-flight), CT acquisition parameters (e.g.
dose, use of contrast), FDG uptake time and blood
glucose level.
▪ Comparative studies: Details of prior PET/CT and/or
other imaging studies which have been directly
compared.
▪ Findings: We divide this heading into primary tumour
(T), nodal metastases (N) and distant metastases (D)
sub-headings, followed by other findings to describe
any incidental findings. For lymphoma we divide the
report into nodal and extra-nodal sub-headings. We
strongly prefer this to an anatomic report (e.g. head,
neck, chest, abdomen/pelvis) as the important
findings are documented first, and incidental findings
last. The PET findings are presented first but are
directly correlated with the associated correlative CT
findings rather than performing sequential or separate
PET and CT reports. An ideal descriptive report
should enable the reader to visualise the findings even
without having access to the images themselves.
Where appropriate to support qualitative findings,
specific measures including standardised uptake
values (SUV), metabolic tumour volume and lesion
dimensions should be included.
▪ Conclusion: This should provide a concise answer to
the clinical question. We include the American Joint
Committee on Cancer (AJCC) TNM stage for staging
scans where our referral-base utilises this staging
schema. For restaging, we summarise findings as a
complete metabolic response, partial metabolic re-
sponse, stable disease or progressive metabolic
disease [14]. Where appropriate, especially when
results are equivocal, we provide guidance to the
referring clinician. To keep the report succinct, we
avoid repetition of interpretative findings in Findings
and descriptive findings in the Conclusion. Where a
single unifying interpretation is not possible, we
provide clinical useful differentials rather than an
exhaustive list of all possibilities and try to indicate
the most efficient means to address ongoing
uncertainty, which might include suggesting an
appropriate biopsy site or recommending further
laboratory or imaging evaluations.
Table 2 Our patient questionnaire that we use routinely to
provide additional history that may assist PET interpretation
• When did you last eat?
• Are you diabetic? If yes, what type of diabetic medications are you
taking? When did you last have them?
• Have you had any surgery, biopsies or day procedures in the last
5 years? Provide a brief list.
• Do you have any prosthetic implants or drainage bags?
• Have you had any recent infections?
• List any other previous illness.
• Do you suffer with any pain at the moment? If so where?
• Have you ever had chemotherapy? When did you last receive this
treatment?
• Have you ever had radiotherapy? When did you last receive this
treatment?
• Are you taking any hormone therapy?
• Are you currently takin any medicines or tablets? Please list.
• Are you or were you ever a smoker?
• For female patients, is there any possibility that you may be pregnant?
When was your last menstrual period?
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We include key images embedded in the report, con-
sisting of serial MIP image demonstrating changes over
time, and selected annotated fused PET/CT and CT
images highlighting key abnormalities. Feedback from
referrers indicates that integration of key images in re-
ports is highly appreciated [15].
Sensitivity versus specificity: what is optimal?
For cancer imaging with FDG PET/CT, we generally aim
to report with high specificity acknowledging the conse-
quent trade-off in sensitivity [16]. In our experience,
high sensitivity reporting may lead to adverse patient
outcomes by resulting in false positive findings and the
potential to deny the patient curative-intent therapies,
whilst also leading to a cycle of further investigations
resulting in patient and physician anxiety. This approach
is extended to incidental findings which are often clinic-
ally irrelevant in the context of patients with advanced
malignancy.
Conclusions
Correct and consistent thresholding of the PET window
is essential for consistent and accurate interpretation.
The PET coronal or cine MIP images provide the key in-
formation needed to obtain an overview that can often
answer the clinical question. Not all metabolically active
abnormalities are malignant and a variety of physiologic
and inflammatory patterns must be recognised. Cohesive
integration of functional and anatomic information pro-
vided by PET and CT, respectively, is essential for cor-
rect interpretation. In doing this, one must not merely
use the PET to locate CT abnormalities which are then
counted and measured. A key paradigm change with
FDG PET/CT is its ability to non-invasively measure
glycolytic metabolism, a hall-mark of aggressive malig-
nancy. Integrating this “metabolic signature” into inter-
pretation provides important information. Whilst the
intensity of FDG uptake often correlates with disease ag-
gressiveness, recognition of aggressive lesions that are
not FDG-avid, and intensely FDG-avid but benign path-
ologies is essential.
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